Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 17/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 15/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 15/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 12/20 | 0.64 |
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.64 |
| ▸ | HRH2 | P25021 | 2/20 | 0.64 |
| ▸ | ADRA1D | P25100 | 11/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 11/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.50 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6054571 | 0.83 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| SCHEMBL6054577 | 0.83 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| SCHEMBL6054581 | 0.82 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| SCHEMBL11470614 | 0.81 | ADRA2A (0.68) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| SCHEMBL11190236 | 0.80 | ADRA2A (0.52) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| SCHEMBL6054561 | 0.80 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL60334 | 0.78 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL20769844 | 0.78 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| SCHEMBL6054545 | 0.77 | ADRA2A (0.71) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| SCHEMBL6054549 | 0.77 | ADRA2A (0.60) | ADRA2AADRA2BADRA2CADRA1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063813-A1 | Organic compounds | CRAWLEY PATRICK E | 2006-03-23 | — | — | US | disclosed |
| EP-1572186-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES VIRUS INFECTIONS USING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS OR CYCLOOXYGENASE-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1556042-A2 | COMBINATIONS OF BENZODITHIAZOLES AND COX-2 INHIBITORS FOR THE TREATMENT OF PAIN | Novartis AG (CH) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004056349-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES VIRUS INFECTIONS USING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS OR CYCLOOXYGENASE-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS | PHARMACIA CORPORATION (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004035030-A2 | COMBINATIONS OF BENZODITHIAZOLES AND COX-2 INHIBITORS FOR THE TREATMENT OF PAIN | NOVARTIS AG (CH) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063813-A1 | Organic compounds | PTGES2, PTGS2, PTGER2 | ADRA2A 1059/4885ADRA2B 1064/4885ADRA2C 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.